Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of Dup 15q or CDKL5 deficiency disorder.~2. Currently taking 1 to 6 antiepileptic drugs (AEDs) at a stable dose.~Exclusion Criteria:~1. Two or more episodes of convulsive status epilepticus per 3 months requiring hospitalization and intubation.~2. Currently receiving a study drug or participated in a clinical study involving another investigational product in the previous month.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Soticlestat Dup 15q (Type: EXPERIMENTAL): Soticlestat tablets twice daily (BID) orally or via gastrostomy tube (G-tube)/ percutaneous endoscopic gastrostomy (PEG) tube, BID. Participants with Dup 15q weighing \<60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
- Soticlestat CDD (Type: EXPERIMENTAL): Soticlestat tablets BID orally or via G-tube/ PEG tube, BID. Participants with CDD weighing \<60 kg at Baseline received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.

Based on this trial design, predict the completion outcome and termination type (if applicable).